Efficacy and Safety of Bisphosphonate Therapy in Children with Osteogenesis Imperfecta: A Systematic Review

Ester B. G. Rijks; Bart C. Bongers; Marloes J. G. Vlemmix; Annemieke M.  Boot; Atty T. H. van Dijk; Ralph J. B. Sakkers; Marco van Brussel

doi:10.1159/000381713

Efficacy and Safety of Bisphosphonate Therapy in Children with Osteogenesis Imperfecta: A Systematic Review

Ester B. G. Rijks, Bart C. Bongers, Marloes J. G. Vlemmix, Annemieke M. Boot, Atty T. H. van Dijk, Ralph J. B. Sakkers, Marco van Brussel^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

61 Citations (Scopus)

Abstract

Background/Aims: To systematically assess contemporary knowledge regarding the effectiveness and safety of bisphosphonates (BPs) in children with osteogenesis imperfecta (OI). Methods: PubMed/MEDLINE, Embase, and Cochrane were searched for eligible articles up to June 2014. Studies eligible for inclusion were (randomized) controlled trials assessing the effects of BPs in children with OI. Methodological quality was assessed independently by 4 reviewers using the Cochrane Collaboration's tool for risk of bias. Results: Ten studies (519 children) were included. Four studies (40%) showed a low risk of bias. All studies investigating lumbar spine areal bone mineral density indicated a significant increase as a result of BP treatment. Most studies observed a significant decrease in fracture incidence. The most frequently reported adverse events were gastrointestinal complaints, fever, and muscle soreness. A significant decrease in (bone) pain due to BP treatment was observed in more than half of the studies. Most studies measuring urinary markers of bone resorption reported a significant decrease. The majority of studies with intravenous treatment showed a significant increase in lumbar projection area, whereas studies with oral treatment did not. Conclusions: Treatment with oral or intravenous BPs in children with OI results in an increase in bone mineral density and seems to be safe and well tolerated. (C) 2015 S. Karger AG, Basel

Original language	English
Pages (from-to)	26-42
Number of pages	17
Journal	Hormone Research in Paediatrics
Volume	84
Issue number	1
DOIs	https://doi.org/10.1159/000381713
Publication status	Published - 2015

Keywords

Osteogenesis imperfecta
Child
Bisphosphonates
Fractures
Bone mineral density
INTRAVENOUS PAMIDRONATE TREATMENT
CONTROLLED-TRIAL
RISEDRONATE
PERSPECTIVES
OLPADRONATE
ASSOCIATION
ADOLESCENTS
ALENDRONATE
FRACTURES
COHORT

Access to Document

10.1159/000381713

Handle.net

Persistent link

Cite this

@article{890252ca43fd4888bb6666965d937f9c,

title = "Efficacy and Safety of Bisphosphonate Therapy in Children with Osteogenesis Imperfecta: A Systematic Review",

abstract = "Background/Aims: To systematically assess contemporary knowledge regarding the effectiveness and safety of bisphosphonates (BPs) in children with osteogenesis imperfecta (OI). Methods: PubMed/MEDLINE, Embase, and Cochrane were searched for eligible articles up to June 2014. Studies eligible for inclusion were (randomized) controlled trials assessing the effects of BPs in children with OI. Methodological quality was assessed independently by 4 reviewers using the Cochrane Collaboration's tool for risk of bias. Results: Ten studies (519 children) were included. Four studies (40%) showed a low risk of bias. All studies investigating lumbar spine areal bone mineral density indicated a significant increase as a result of BP treatment. Most studies observed a significant decrease in fracture incidence. The most frequently reported adverse events were gastrointestinal complaints, fever, and muscle soreness. A significant decrease in (bone) pain due to BP treatment was observed in more than half of the studies. Most studies measuring urinary markers of bone resorption reported a significant decrease. The majority of studies with intravenous treatment showed a significant increase in lumbar projection area, whereas studies with oral treatment did not. Conclusions: Treatment with oral or intravenous BPs in children with OI results in an increase in bone mineral density and seems to be safe and well tolerated. (C) 2015 S. Karger AG, Basel",

keywords = "Osteogenesis imperfecta, Child, Bisphosphonates, Fractures, Bone mineral density, INTRAVENOUS PAMIDRONATE TREATMENT, CONTROLLED-TRIAL, RISEDRONATE, PERSPECTIVES, OLPADRONATE, ASSOCIATION, ADOLESCENTS, ALENDRONATE, FRACTURES, COHORT",

author = "Rijks, {Ester B. G.} and Bongers, {Bart C.} and Vlemmix, {Marloes J. G.} and Boot, {Annemieke M.} and {van Dijk}, {Atty T. H.} and Sakkers, {Ralph J. B.} and {van Brussel}, Marco",

year = "2015",

doi = "10.1159/000381713",

language = "English",

volume = "84",

pages = "26--42",

journal = "Hormone Research in Paediatrics",

issn = "1663-2818",

publisher = "KARGER",

number = "1",

}

TY - JOUR

T1 - Efficacy and Safety of Bisphosphonate Therapy in Children with Osteogenesis Imperfecta

T2 - A Systematic Review

AU - Rijks, Ester B. G.

AU - Bongers, Bart C.

AU - Vlemmix, Marloes J. G.

AU - Boot, Annemieke M.

AU - van Dijk, Atty T. H.

AU - Sakkers, Ralph J. B.

AU - van Brussel, Marco

PY - 2015

Y1 - 2015

N2 - Background/Aims: To systematically assess contemporary knowledge regarding the effectiveness and safety of bisphosphonates (BPs) in children with osteogenesis imperfecta (OI). Methods: PubMed/MEDLINE, Embase, and Cochrane were searched for eligible articles up to June 2014. Studies eligible for inclusion were (randomized) controlled trials assessing the effects of BPs in children with OI. Methodological quality was assessed independently by 4 reviewers using the Cochrane Collaboration's tool for risk of bias. Results: Ten studies (519 children) were included. Four studies (40%) showed a low risk of bias. All studies investigating lumbar spine areal bone mineral density indicated a significant increase as a result of BP treatment. Most studies observed a significant decrease in fracture incidence. The most frequently reported adverse events were gastrointestinal complaints, fever, and muscle soreness. A significant decrease in (bone) pain due to BP treatment was observed in more than half of the studies. Most studies measuring urinary markers of bone resorption reported a significant decrease. The majority of studies with intravenous treatment showed a significant increase in lumbar projection area, whereas studies with oral treatment did not. Conclusions: Treatment with oral or intravenous BPs in children with OI results in an increase in bone mineral density and seems to be safe and well tolerated. (C) 2015 S. Karger AG, Basel

AB - Background/Aims: To systematically assess contemporary knowledge regarding the effectiveness and safety of bisphosphonates (BPs) in children with osteogenesis imperfecta (OI). Methods: PubMed/MEDLINE, Embase, and Cochrane were searched for eligible articles up to June 2014. Studies eligible for inclusion were (randomized) controlled trials assessing the effects of BPs in children with OI. Methodological quality was assessed independently by 4 reviewers using the Cochrane Collaboration's tool for risk of bias. Results: Ten studies (519 children) were included. Four studies (40%) showed a low risk of bias. All studies investigating lumbar spine areal bone mineral density indicated a significant increase as a result of BP treatment. Most studies observed a significant decrease in fracture incidence. The most frequently reported adverse events were gastrointestinal complaints, fever, and muscle soreness. A significant decrease in (bone) pain due to BP treatment was observed in more than half of the studies. Most studies measuring urinary markers of bone resorption reported a significant decrease. The majority of studies with intravenous treatment showed a significant increase in lumbar projection area, whereas studies with oral treatment did not. Conclusions: Treatment with oral or intravenous BPs in children with OI results in an increase in bone mineral density and seems to be safe and well tolerated. (C) 2015 S. Karger AG, Basel

KW - Osteogenesis imperfecta

KW - Child

KW - Bisphosphonates

KW - Fractures

KW - Bone mineral density

KW - INTRAVENOUS PAMIDRONATE TREATMENT

KW - CONTROLLED-TRIAL

KW - RISEDRONATE

KW - PERSPECTIVES

KW - OLPADRONATE

KW - ASSOCIATION

KW - ADOLESCENTS

KW - ALENDRONATE

KW - FRACTURES

KW - COHORT

U2 - 10.1159/000381713

DO - 10.1159/000381713

M3 - Article

SN - 1663-2818

VL - 84

SP - 26

EP - 42

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

IS - 1

ER -

Efficacy and Safety of Bisphosphonate Therapy in Children with Osteogenesis Imperfecta: A Systematic Review

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this